Abstract
In this article we studied serum leptin levels in children receiving long-term carbamazepine (CBZ) therapy (mean 3.4 years) to determine whether or not there was a relationship between serum leptin level and CBZ therapy. The study includes 14 patients followed with the diagnosis of epilepsy and treated long term CBZ, and 19 healthy children. Only two (14%) patients complained about overeating and weight gain. We did not find any significant difference for age, sex, body mass index and serum leptin levels between the study and control groups (p > 0.05). If a markedly weight gain was seen in the study group, a higher levels of serum leptin could be expected. Additionally, there was not a relationship between serum leptin and CBZ levels (r: 0.48; p > 0.05). Our preliminary findings showed that long-term use of CBZ did not cause markedly weight gain in childhood and serum leptin levels did not differ from the control subjects. We think that more extensive studies should be performed about this subject.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
